NEW YORK (GenomeWeb) – Qiagen said today that its Artus CMV QS-RGQ molecular diagnostic kit for use on the QiaSymphony platform has received premarket approval from the US Food and Drug Administration.

The real-time PCR assay is designed to be used with human plasma samples, and is intended to aid in the management of solid organ transplant patients who are undergoing anti-cytomegalovirus therapy.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.